Immuron announces record Travelan® sales globally, Australia and USA
Immuron (ASX: IMC; NASDAQ: IMRN) has reported record global sales for its over-the-counter immune supplement Travelan® in FY 2024. Global sales reached AUD$4.9 million, up 174% from the previous year. Australia led with AUD$3.7 million in sales, a 223% increase, while the USA achieved record sales of AUD$1.1 million, up 74%. The June 2024 quarter saw significant growth, with global sales up 253% year-over-year to AUD$1.3 million.
The company attributes this success to increased brand awareness investments and plans further growth in North America through increased brand investment and distribution. The sales surge aligns with rising international travel, as reported by the Australian Bureau of Statistics and the U.S. International Trade Administration.
- Record global Travelan® sales of AUD$4.9 million in FY 2024, up 174% year-over-year
- Australia sales increased 223% to AUD$3.7 million in FY 2024
- USA achieved record annual sales of AUD$1.1 million, up 74% from previous year
- June 2024 quarter global sales up 253% year-over-year to AUD$1.3 million
- Plans for increased brand investment and distribution in North America for FY 2025
- USA sales in June 2024 quarter down 1% compared to the previous quarter
The recent sales data of Travelan® provided by Immuron Limited indicates a substantial growth across multiple markets, including Australia, the USA and Canada. This surge in sales suggests an effective marketing strategy and increased product awareness. The 174% rise in global sales and 223% increase in Australia highlight strong domestic demand, potentially driven by a post-pandemic recovery in travel and consumer health consciousness.
Interestingly, USA sales increased by 74% for the year, setting a new record despite a modest dip from the previous quarter. This could be a reflection of seasonal buying patterns or temporary market fluctuations. The 6637% increase in Canada, although from a low base, suggests a significant market penetration and growth opportunity. Investors should monitor if this trend continues, particularly with Immuron planning further investments in brand awareness and distribution.
From a financial standpoint, these growth figures are promising. However, it's important to consider the sustainability of these sales trends and the company's ability to maintain or improve its market position. The increased sales should positively impact the company's revenue and potentially its stock price, but ongoing investment costs should also be factored in.
The impressive sales performance of Travelan® in FY 2024 highlights a growing demand for over-the-counter immune supplements targeting gastrointestinal health. This surge can be attributed to several factors, including increased global travel, heightened health awareness post-pandemic and effective marketing strategies.
The notable 200% increase in Australian sales and 546% increase in USA sales during the June quarter are indicative of a strong, possibly seasonal, demand. The correlation with increases in international travel—April 2024 travel data showing 29% higher Australian returns and 8% higher U.S. departures—supports the view that travel health products are in higher demand as travel resumes.
For investors, this news underscores the potential for continued growth in the health supplement market, particularly products like Travelan®. Long-term prospects look favorable, provided Immuron sustains its investment in marketing and distribution. Additionally, market expansion into regions like Canada demonstrates the company's proactive approach to tapping new markets.
Travelan®'s strong sales performance in FY 2024 points to a successful positioning within the health supplement market, particularly those targeting gastrointestinal issues. This growth reflects an increasing consumer awareness and trust in preventative health measures, especially during travel.
Given the product's focus on reducing the risk of travelers' diarrhea, the uptick in travel as reflected by the Australia Bureau of Statistics and International Trade Administration data likely fueled this demand. The increased sales in the USA and Australia indicate effective penetration into markets where travel is rebounding post-pandemic.
For stakeholders, it's important to note the potential for this product to continue gaining traction as travel norms stabilize. The company's strategic investments in brand awareness and distribution are critical for maintaining momentum. However, it will be essential to monitor the competitive landscape for similar products that could impact future growth.
Sales Highlights:
| Global | • | FY 2024 AUD |
| • | June 2024 Quarter AUD | |
| Australia | • | FY 2024 AUD |
| • | June 2024 Quarter AUD | |
| | ||
| USA | • | FY 2024 Record sales of AUD |
| • | June 2024 Quarter AUD | |
| Canada | • | FY2024 AUD |
| |
MELBOURNE, Australia, July 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce record sales (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract.
Flavio Palumbo, Chief Commercial Officer, said, “We continue to be excited by the strong sales results on Travelan®. Immuron’s investment to drive awareness of the Travelan® brand has seen continued strong sales results in Australia. We were incredibly pleased to achieve record U.S. sales in FY24. We hope to achieve strong North American growth in FY25 on the back of planned increased brand investment and distribution.”
Australia
Sales of Travelan® increased
Consistent with the increase in June 2024 quarter sales, the Australian Bureau of Statistics reported short term resident returns in April 2024 were
USA
We achieved a new annual record. The previous highest annual USA sales was AUD
Sales of Travelan® increased
Sales of Travelan® increased
Immuron’s experience in the USA follows the International Trade Administration Total U.S. citizen international visitor departures from the United States in April 2024 being
- www.abs.gov.au/statistics/industry/tourism-and-transport/overseas-arrivals-and-departures-australia/latest-release
- www.trade.gov/us-international-air-travel-statistics-i-92-data
This release has been authorised by the directors of Immuron Limited.
COMPANY CONTACT:
Steven Lydeamore
Chief Executive Officer
Ph: +61 (0)3 9824 5254
info@immuron.com
About Travelan®
Travelan® is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting Travelers’ Diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan® is a highly purified tabletized preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with Travelers’ Diarrhea. In Australia, Travelan® is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers’ Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers’ Diarrhea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection.
About Travelers’ Diarrhea
Travelers’ Diarrhea is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating, and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic Escherichia coli (ETEC) playing a dominant causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections with Salmonella spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are often confused with Travelers’ Diarrhea as they may be contracted while travelling and initial symptoms are often indistinguishable.
About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.
For more information visit: http://www.immuron.com
FORWARD-LOOKING STATEMENTS:
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
FAQ
What were Immuron's (IMRN) global Travelan® sales for FY 2024?
How much did Immuron's (IMRN) Travelan® sales grow in Australia for FY 2024?
What was Immuron's (IMRN) Travelan® sales performance in the USA for FY 2024?
How did Immuron's (IMRN) Travelan® sales perform in the June 2024 quarter globally?
What are Immuron's (IMRN) plans for growth in North America for FY 2025?
